Publication year
2017Source
Nature Reviews. Urology, 14, 4, (2017), pp. 244-255ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Urology
Journal title
Nature Reviews. Urology
Volume
vol. 14
Issue
iss. 4
Page start
p. 244
Page end
p. 255
Subject
Radboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Intravesical immunotherapy with live attenuated BCG remains the standard of care for patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Most patients initially respond, but recurrence is frequent and progression to invasive cancer is a concern. No established and effective intravesical therapies are available for patients whose tumours recur after BCG, representing a clinically important unmet need. Development and discovery of treatment options for BCG-unresponsive NMIBC is a high priority in order to decrease the morbidity, burden of health-care expenditures, and mortality related to bladder cancer. This Review of treatment options after BCG failure focuses on principles of optimal management emerging therapies, thus enabling a synthesis of recommendations for management for such patients.
This item appears in the following Collection(s)
- Academic publications [202786]
- Faculty of Medical Sciences [80017]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.